- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06413615
A Study of FDA022-BB05 in Advanced/Metastatic Solid Tumors
A Phase 2, Multicenter, Open-Label Study to Assess the Efficacy, Safety, Tolerability and Pharmacokinetics of FDA022-BB05 in Patients With Advanced/Metastatic Solid Tumors
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Jian Zhang, MD
- Phone Number: 85000 021-64175590
- Email: syner2000@163.com
Study Locations
-
-
-
Shanghai, China
- Fudan University Shanghai Cancer Center
-
Contact:
- Jian Zhang, MD
- Phone Number: 85000 021-64175590
- Email: syner2000@163.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Subjects fully understand and voluntarily participate in this study and sign informed consent.
Left Ventricular Ejection Fraction (LVEF) ≥ 50% within 28 days prior to first dose.
Eastern Cooperative Oncology Group performance status( PS) of 0 or 1. Life expectancy ≥ 3 months.
Histopathologically or cytologically confirmed advanced/unresectable or metastatic solid malignant tumors that is refractory to or intolerable with standard treatment, or for which no standard treatment is available:
Cohort A: Pathologically documented breast cancer that:
- Is unresectable or metastatic.
- Has a history of low HER2 expression, defined as IHC 2+/ISH- or IHC 1+ (ISH- or untested).
- For HR-positive participants, is documented refractory to endocrine therapy, defined as having progressed on at least 1 endocrine therapy and determined by the investigator that subject would no longer benefit from further treatment from endocrine therapy.
- Was never previously HER2-positive(IHC 3+ or IHC 2+/ISH+) on prior pathology testing or was historically HER2 IHC 0 only.
Cohort B: Pathologically documented endometrial cancer that:
- Is unresectable or metastatic.
- Has a history of HER2 expression, defined as HER2 1+, 2+, or 3+ score on immunohistochemistry (IHC).
- Have had at least one prior line of platinum-based therapy (in any setting).
- Was never previously received other ADC anti-tumor treatment.
Cohort C: Metastatic or advanced solid tumor that are HER2 overexpression or mutation(Including urothelial cancer, colorectal adenocarcinoma and non-small cell lung cancer).
Exclusion Criteria:
- A treatment history of antibody-drug conjugate containing topoisomerase I inhibitors.
Subjects with one of the following conditions prior to first dose, including, but not limiting to:A major operation or severe trauma history within 4 weeks; A history of chemotherapy, targeted therapy, anti-angiogenesis therapy, biotherapy, immunotherapy, radiotherapy or other anti-tumor therapy within 4 weeks; A history of endocrine therapy within 3 weeks; A history of autologous stem cell transplant within 3 months.
Subjects with other malignant tumors in the past three years (not including cured non-melanoma skin basal cell carcinoma, cervical carcinoma in situ and other malignancies of low malignant potential that have been effectively controlled without treatment).
Subjects with symptomatic CNS metastasis (for example, cerebral edema requiring glucocorticoids therapy, or progressive CNS metastasis), not including prior cerebral and meningeal metastasis that is confirmed stable with MRI and without systematic glucocorticoids therapy.
Adverse reactions from the previous anti-tumor treatment have not yet recovered (>Grade 2 in NCI-CTCAE 5.0, with exception of alopecia and pigmentation or other adverse reactions judged no safety risk by the investigator).
Subjects with clinically significant cardiovascular or cerebrovascular disease, including, but not limiting to:
a medical history of symptomatic Congestive Heart Failure (CHF) (NYHA classes II-IV) or serious cardiac arrhythmia.
a medical history of myocardial infarction or unstable angina within 6 months prior to screening; a QTc prolongation to > 450 millisecond (ms) in males and > 470 ms in females.
Subjects with a medical history of interstitial lung disease (ILD)/pneumonia in need of glucocorticoids intervention,or with interstitial lung disease, or suspicious ILD by imaging detection at screening.
Subjects with any uncontrolled active infection within 1 week prior to first dose.
Subjects with concomitant disease potentially increasing toxicological risk. Known allergy to protein preparation or any protein drug with similar structure to FDA022-BB05.
Subjects with a History of alcohol abuse or psychotropic/narcotic drug abuse; Pregnant or lactating women. Subjects with poor compliance, or not suitable for this study as determined by the investigator due to other reasons.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: HER2 Low Metastatic/Recurrent Breast Cancer
Enrolled Subjects will receive a 5.4 mg/kg IV dose of FDA022-BB05 on Day 1 of each cycle Q3W
|
Monoclonal antibody-drug conjugate for injection
|
Experimental: HER2 Expressing Metastatic/Recurrent Endometrial Cancer
Enrolled Subjects will receive a 5.4 mg/kg IV dose of FDA022-BB05 on Day 1 of each cycle Q3W
|
Monoclonal antibody-drug conjugate for injection
|
Experimental: HER2 Overxpressing/Mutant Metastatic/Recurrent Solid tumor
Enrolled Subjects will receive a 5.4 mg/kg IV dose of FDA022-BB05 on Day 1 of each cycle Q3W
|
Monoclonal antibody-drug conjugate for injection
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Objective Response Rate (ORR)
Time Frame: up to 24 month
|
The percentage of patients with CR and PR assessed by investigators according to RECIST v 1.1
|
up to 24 month
|
Occurrence of adverse events (AEs) and serious adverse events (SAEs)
Time Frame: up to 24 month
|
Occurrence of AEs and SAEs graded according to NCI CTCAE v5.0.
|
up to 24 month
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Duration of response (DoR)
Time Frame: up to 24 month
|
DOR is defined as the time from the date of first documented response until the date of documented progression or death.
|
up to 24 month
|
Disease control rate (DCR)
Time Frame: up to 24 month
|
DCR is the percentage of subjects who have a best overall response of complete response (CR) or partial response (PR) or stable disease (SD).
|
up to 24 month
|
Progression free survival (PFS)
Time Frame: up to 24 month
|
PFS is the time from date of first dose of study treatment until the date of objective disease progression or death.
|
up to 24 month
|
Overall survival (OS)
Time Frame: up to 24 month
|
OS is the time from date of first dose of study treatment until death due to any cause.
|
up to 24 month
|
Pharmacokinetic (PK) Analysis: Area Under the Concentration Versus Time Curve (AUC) of Serum FDA022-BB05 Following First Dose
Time Frame: From cycle1 to Cycle10 (each cycle is 21 days. )
|
The serum PK parameters of FDA022-BB05 and its analytes for area under the concentration-versus-time curve from time 0 to the last quantifiable concentration as calculated by the linear-up log-down trapezoidal method (AUClast) and AUC from time 0 to infinity (AUCinf) elimination rate constant associated with the terminal phase were estimated using standard non-compartmental methods.
|
From cycle1 to Cycle10 (each cycle is 21 days. )
|
Pharmacokinetic Analysis: Maximum (Peak) Observed Serum Concentration (Cmax) of Serum FDA022-BB05 Following First Dose
Time Frame: From cycle1 to Cycle10 (each cycle is 21 days. )
|
The serum PK parameters Maximum (peak) Observed serum concentration of FDA022-BB05 and its analytes were estimated using standard non-compartmental method.
|
From cycle1 to Cycle10 (each cycle is 21 days. )
|
Pharmacokinetic Analysis: Time of Maximum Plasma Concentration (Tmax) of Serum FDA022-BB05 Following First Dose
Time Frame: From cycle1 to Cycle10 (each cycle is 21 days. )
|
The serum PK parameters of Time of maximum plasma concentration (Tmax) for FDA022-BB05 and its analytes were estimated using standard non-compartmental methods.
|
From cycle1 to Cycle10 (each cycle is 21 days. )
|
Pharmacokinetic Analysis: Terminal Elimination Half-life (t1/2) of Serum FDA022-BB05 Following First Dose
Time Frame: From cycle1 to Cycle10 (each cycle is 21 days. )
|
The serum PK parameters of Terminal elimination half-life for FDA022-BB05 and its analytes was estimated using standard non-compartmental methods.
|
From cycle1 to Cycle10 (each cycle is 21 days. )
|
Number of participants who developed measurable anti-drug antibodies
Time Frame: up to 24 month
|
Individual participant data and descriptive statistics will be provided for data at each time point.
|
up to 24 month
|
Collaborators and Investigators
Investigators
- Principal Investigator: Jian Zhang, MD, Fudan University
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- F0034-201
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Advanced Solid Tumor
-
Aadi Bioscience, Inc.RecruitingAdvanced Solid Tumor | Tumor | Tumor, SolidUnited States
-
Impact Therapeutics, Inc.RecruitingSolid Tumor | Advanced Solid TumorChina, Taiwan, United States, Australia
-
BeiGeneRecruitingSolid Tumor | Advanced Solid TumorUnited States, New Zealand, Australia, China
-
Zhuhai Yufan Biotechnologies Co., LtdRecruitingAdvanced Solid Tumor | Advanced Solid MalignanciesChina
-
Zhuhai Yufan Biotechnologies Co., LtdRecruitingAdvanced Solid Tumor | Advanced Solid MalignanciesUnited States
-
Pyxis Oncology, IncRecruiting
-
Neurogene Inc.Merck Sharp & Dohme LLCActive, not recruitingSolid Tumor | Advanced Solid TumorUnited States, Australia, Canada
-
EMD Serono Research & Development Institute, Inc.Merck KGaA, Darmstadt, GermanyCompletedSolid Tumor | Advanced Solid TumorSpain, United States, Netherlands, United Kingdom
-
Jazz PharmaceuticalsMerck Sharp & Dohme LLCRecruitingAdvanced Solid Tumor | Metastatic Solid TumorUnited States
-
PharmaEngineNot yet recruitingAdvanced Solid Tumor | Metastatic Solid Tumor
Clinical Trials on FDA022-BB05
-
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co...Recruiting